SUMMARY The commonly occurring short stature in the condition of thalassaemia major was investigated with respect to the possible role of the somatomedin growth factor low molecular weight non-suppressible insulin-like activity (NSILAs). Nineteen affected patients (12 boys, 7 girls) aged between 2 and 21 years were studied. Twelve of them were on or below the 10th centile for height, of whom 7 were on or below the 3rd centile for height. Serum immunoreactive growth hormone responses to exercise were normal in 9 of 11 subjects tested. Using an isolated fat cell bioassay NSILAs was undetectable in 10 and was more than 2 SD below the normal mean value in the other 9 subjects. High molecular weight NSILA (not a growth factor) was very low or undetectable in all 9 subjects tested. Low molecular weight NSILAs did not show the normal correlation with age in childhood, nor was there any correlation with height, height velocity, or bone age. The 2 children above the 50th centile for height had undetectable NSILAs. There was no evidence of iron or ferritin interfering in the bioassay, and mixing experiments showed no evidence of inhibitory activity towards NSILAs in thalassaemic sera. Low circulating levels ofthe somatomedin NSILAs may contribute to the short stature in thalassaemia major, but other factors may permit normal growth in some affected children.
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Desferrioxamine, an iron-chelating agent, had been given to each child with every blood transfusion since diagnosis. Nine of the children had been started on a programme of intensive treatment with desferrioxamine by daily intramuscular injection during the previous I to 8 years. During the 4 months preceding this study these 9 children and another 6 were begun on an alternative regimen of daily desferrioxamine by nocturnal subcutaneous infusion.
The Table shows the results of investigations previously performed in some of the children. Bone age was delayed (by more than 1 J years) in 5 children (of 14 studied), and serum iron and ferritin levels were greatly increased in all children tested. Mild disturbances in liver function were noted in 12 of the 14 children tested, the most common abnormality being moderately raised aspartate transaminase levels. Serum proteins, including serum albumin, were normal in all except one child.
Exercise-induced GH stimulation tests were performed in 11 of the 19 children, blood samples being taken before, immediately after, and 20 minutes after vigorous exercise on a bicycle ergometer or running upstairs. Serum GH was estimated by a radioimmunoassay using polyethylene glycol to precipitate antibody-bound hormone. For measurement of NSILA, 10-20 ml of blood was collected from each child immediately before transfusion. Serum was separated and stored at -20cC for up to 3 months before assay. NSILA was estimated by a previously described bioassay'3 using the incorporation of '4C-glucose into isolated rat adipocytes in the presence of excess anti-insulin antibody. Low molecular weight NSILAs was estimated after an initial acid-ethanol extraction of serum samples before incorporation in the bioassay.'3 High molecular weight NSILA was estimated by using unextracted but dialysed serum samples in the bioassay. Activity measured in these circumstances is essentially that of the high molecular weight form only.14 Results in both assays were expressed as potencies compared with a similarly treated reference pool ofnormal serum defined as 1 U/ml. NSILAs was also estimated in a control group of 6 prepubertal boys aged [14] [15] [16] U/ml, n = 2; extract 103 ± 0 24, mean ± SD, n = 4) by the addition respectively of thalassaemic sera (potency 0 14, 0 34 U/ml, n = 2) or extracts (0 07 ± 0 05, mean ± SD, n = 4). The possible inhibitory effects of iron or ferritin were examined since, as expected, the sera of these thalassaemic children contained high levels of iron (29-55 ,umol/l (162-308 ,ug/100 ml); normal range 10-30 ,umol/l (56-168 ,ug/100 ml)) and ferritin (>4500 F±mol/l (>2000 ,ug/l); normal range Vmol/l F±g/l)). Dialysis of unextracted sera had little effect on these levels. However, acidethanol extraction led to negligible levels of iron and low levels of ferritin (270-1200 ,umol/l; 120-540 ,ug/l) in thalassaemic sera. Addition of ferritirk (1100 ,umol/l; 500 [Ag/l) to normal serum extracts (potency 1 U/ml, defined) however led to no change in measured NSILAs (potency 1-06 U/mi).
Discussion
Short stature is common, although not universal, in thalassaemia major. Several studies have reported 
